Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1977 Feb;11(2):307–311. doi: 10.1128/aac.11.2.307

Experimental Herpes Simplex Virus Type 1 Encephalitis: Treatment with 5-Trifluoromethyl-2′-Deoxyuridine

D W Clough *, J Rodney Parkhurst 1
PMCID: PMC351972  PMID: 192143

Abstract

5-Trifluoromethyl-2′-deoxyuridine (F3dThd) was evaluated for its neurotoxicity and for its ability to increase the life span of mice injected intracerebrally with herpes simplex virus type 1 (HSV-1) and F3dThd simultaneously. F3dThd showed no neurotoxicity at the highest concentration tested (100 mg/kg). Mice injected intracerebrally with HSV-1 died within 5 days postinfection. However, all mice injected concurrently with HSV-1 and 100 mg of F3dThd per kg lived through the termination of the experiment (60 days). Protection of mice from HSV-1 encephalitis by F3dThd has been shown to be dose dependent, with 100, 75, 50, and 25 mg of F3dThd per kg yielding a survival rate of 100, 90, 50, and 10%, respectively. HSV-1 titers in mouse brains receiving HSV-1 and 100 mg of F3dThd per kg concurrently were 100- to 1,000-fold lower at 2 to 4 days postinfection than control mice receiving HSV-1 alone. F3dThd was shown not to stimulate interferon production. Encephalitis caused by a ribonucleic acid virus, encephalomyocarditis virus, was not modified by F3dThd treatment.

Full text

PDF
307

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akerfeldt S., Westin G., Jansson T. Aromatic sulfonic acids as viral inhibitors. Structure-activity study using rhino, adeno 3, herpes simplex, and influenza viruses. J Med Chem. 1971 Jul;14(17):595–600. [PubMed] [Google Scholar]
  2. Allen L. B., Sidwell R. W. Target-organ treatment of neurotropic virus diseases: efficacy as a chemotherapy tool and comparison of activity of adenine arabinoside, cytosine arabinoside, idoxuridine, and trifluorothymidine. Antimicrob Agents Chemother. 1972 Sep;2(3):229–233. doi: 10.1128/aac.2.3.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ansfield F. J., Ramirez G. Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep. 1971 Apr;55(2):205–208. [PubMed] [Google Scholar]
  4. Bresnick E., Williams S. S. Effects of 5-trifluoromethyldeoxyuridine upon deoxythymidine kinase. Biochem Pharmacol. 1967 Mar;16(3):503–507. doi: 10.1016/0006-2952(67)90097-4. [DOI] [PubMed] [Google Scholar]
  5. Gilbert D. N., Johnson M. T., Luby J. P., Sanford J. P. Herpesvirus hominis type I encephalitis treated with cytarabine, an unresolved problem in encephalitis. Medicine (Baltimore) 1973 Jul;52(4):331–338. doi: 10.1097/00005792-197307000-00012. [DOI] [PubMed] [Google Scholar]
  6. HEIDELBERGER C., ANDERSON S. W. FLUORINATED PYRIMIDINES. XXI. THE TUMOR-INHIBITORY ACTIVITY OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE. Cancer Res. 1964 Dec;24:1979–1985. [PubMed] [Google Scholar]
  7. HEIDELBERGER C., PARSONS D. G., REMY D. C. SYNTHESES OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE. J Med Chem. 1964 Jan;7:1–5. doi: 10.1021/jm00331a001. [DOI] [PubMed] [Google Scholar]
  8. Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. KAUFMAN H. E., HEIDELBERGER C. THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS. Science. 1964 Aug 7;145(3632):585–586. doi: 10.1126/science.145.3632.585. [DOI] [PubMed] [Google Scholar]
  10. Kaiser A. B., McGee Z. A. Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med. 1975 Dec 11;293(24):1215–1220. doi: 10.1056/NEJM197512112932401. [DOI] [PubMed] [Google Scholar]
  11. Kaufmann H. E. In vivo studies with antiviral agents. Ann N Y Acad Sci. 1965 Jul 30;130(1):168–180. doi: 10.1111/j.1749-6632.1965.tb12550.x. [DOI] [PubMed] [Google Scholar]
  12. Oie H. K., Buckler C. E., Uhlendorf C. P., Hill D. A., Baron S. Improved assays for a variety of interferons. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1178–1181. doi: 10.3181/00379727-140-36636. [DOI] [PubMed] [Google Scholar]
  13. Parkhurst J. R., Danenberg P. V., Heidelberger C. Growth inhibition of cells in cultures and of vaccinia virus infected HeLa cells by derivatives of trifluorothymidine. Chemotherapy. 1976;22(3-4):221–231. doi: 10.1159/000221929. [DOI] [PubMed] [Google Scholar]
  14. Plummer G., Ingerson A. P. Iododeoxyuridine and herpesviral encephalitis: lack of inhibitory action against low-grade viral replication. Antimicrob Agents Chemother. 1974 Jun;5(6):672–673. doi: 10.1128/aac.5.6.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reyes P., Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol. 1965 Jul;1(1):14–30. [PubMed] [Google Scholar]
  16. Tone H., Heidelberger C. Fluorinated pyrimidines. XLIV. Interaction of 5-trifluoromethyl-2'-deoxyuridine 5'-triphosphate with deoxyribonucleic acid polymerases. Mol Pharmacol. 1973 Nov;9(6):783–791. [PubMed] [Google Scholar]
  17. Umeda M., Heidelberger C. Comparative studies of fluorinated pyrimidines with various cell lines. Cancer Res. 1968 Dec;28(12):2529–2538. [PubMed] [Google Scholar]
  18. Wellings P. C., Awdry P. N., Bors F. H., Jones B. R., Brown D. C., Kaufman H. E. Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers. Am J Ophthalmol. 1972 Jun;73(6):932–942. doi: 10.1016/0002-9394(72)90463-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES